priors.science/reviews/adhd-pharmacotherapy

Adhd Pharmacotherapy

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
54primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 4 Likely · 2 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Viloxazine and guanfacine as approved non-stimulant alternatives for ADHDNon StimulantLikely82%10
Atomoxetine effective non-stimulant option for attention-deficit/hyperactivity disorderNon StimulantLong-standingLikely80%9
Stimulants cause minor cardiovascular changes with rare serious eventsSafety MonitoringLikely78%10
Stimulants most effective pharmacotherapy for attention-deficit/hyperactivity disorderStimulant EfficacyLikely78%9
Stimulants reduce attention-deficit/hyperactivity disorder symptoms in adultsStimulant EfficacyUncertain69%6
Long-term stimulant use does not reliably prevent functional impairments in ADHDLong Term OutcomesUncertain61%10
Track Adhd Pharmacotherapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.